GI Dynamics Announces Worldwide EndoBarrier Registry Data for 871 Patients Presented at EASD 2019
(World News Science)

BOSTON and SYDNEY - 20 September 2019 - GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce positive data from the Association of British Clinical Diabetologists (ABCD) Worldwide EndoBarrier Registry evaluating the benefit: risk of EndoBarrier, presented by Katharina Laubner, M.D. of the University of Freiburg. The data was presented at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona, Spain on 19 September 2019. The poster `Duodenal-jejunal Bypass Liner (DJBL) for Treatment of Type 2 Diabetes and Obesity - The Risk: Benefit Ratio from the...